59 results about "Methotrexate" patented technology

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

The invention belongs to the technical field of biological detection, and particularly relates to a method for synchronously and quantitatively detecting various folic acid metabolism related substances in trace plasma or serum, which comprises the following steps of: detecting a pretreated trace plasma or serum sample by adopting a liquid chromatography-tandem mass spectrometry method; the following nine folic acid metabolism related substances are synchronously and quantitatively detected: 5-formyl tetrahydrofolic acid, folic acid, 5-methyl tetrahydrofolic acid, S-adenosine-L-methionine, S-adenosine-L-homocysteine, vitamin B12, pyridoxamine, pyridoxine and pyridoxal. The invention further relates to application of the detection method in related detection of child neurodevelopment. According to the detection method, only trace plasma or serum is used, methotrexate is used for replacing an expensive isotope internal standard for more economical detection, and nine folate metabolism related substances can be accurately quantified at the same time. Therefore, the detection method disclosed by the invention has important clinical significance and wide market application prospect.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

The application discloses a use of total iridoid glycosides in radix morindae officinalis in preparation of a medicine for reducing side effects of methotrexate, and the total iridoid glycosides in radix morindae officinalis are effective traditional Chinese medicine components prepared by extraction and separation from radix morindae officinalis medicinal materials. The total iridoid glycosides in radix morindae officinalis and main component crystal larkspur glycoside are combined with methotrexate to treat rheumatoid arthritis rats, and the animal experiment proves that the combined administration can effectively treat inflammation of the rheumatoid arthritis rats, and can inhibit bone loss, especially can effectively reduce side effects caused by methotrexate, reduce damage caused by methotrexate to the organism, make the application more safe and effective, and provide a new treatment strategy for rheumatoid arthritis.

The present invention discloses methods to prevent gout flares using IL-1β inhibitors. A method of treating gout patients using methotrexate, canakinumab, and pegloticase is described.

The present invention relates generally to genomics. In particular, the specification teaches a method of predicting subjects at risk of rheumatoid arthritis and the responsiveness of a subject towards methotrexate (MTX) treatment.

The present invention provides a fully human antibody that specifically binds to human FLT3 within extracellular domains 4 or 5 with high affinity. In particular disclosed is an antibody that specifically binds human FLT3 (SEQ ID NO. 43), comprising a CDRH1 having the sequence SYYMH (SEQ ID NO:2), a CDRH2 having the sequence IINPSGGSTSYAQKFQG (SEQ ID NO:3), a CDRH3 having the sequence GVGAHDAFDI (SEQ ID NO:4) or VVAAAVADY (SEQ ID NO:5), a CDRL1 having the sequence RSSQSLLHSNGNNYLD (SEQ ID NO:6) or RSSQSLLHSNGYNYLD (SEQ ID NO:7), a CDRL2 having the sequence LGSNRAS (SEQ ID NO:8), and a CDRL3 having the sequence MQGTHPAIS (SEQ ID NO:9) or MQSLQTPFT (SEQ II) NO: 11). The invention further provides a pharmaceutical composition for treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.

The present application relates to a methotrexate detection kit. Specifically, the 6-phosphogluconate dehydrogenase mutant of the present application comprises one mutation or a combination thereof selected from the following: D306C, D375C, G426C, compared with wild-type 6-phosphogluconate dehydrogenase. The detection kit prepared using the 6-phosphogluconate dehydrogenase mutant of the present application has strong specificity, high sensitivity, convenient operation, short detection time, accurate quantification, and is suitable for high-throughput detection.

The invention provides a traditional Chinese medicine composition with an anti-inflammatory effect and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following functional components: oldenlandia diffusa, rhizoma smilacis glabrae, astragalus membranaceus, radix aconiti carmichaeli, sargentgloryvine stem, madder, centipede and liquorice. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 30-45 parts of oldenlandia diffusa, 30-45 parts of rhizoma smilacis glabrae, 30-45 parts of astragalus membranaceus, 10-15 parts of radix aconiti carmichaeli, 10-20 parts of sargentgloryvine stem, 10-15 parts of madder, 2-4 parts of centipede and 6-9 parts of liquorice through mixing and water extraction, and the components have a synergistic effect, so that the traditional Chinese medicine composition has the effects of detoxifying, expelling toxins and diminishing swelling, has a remarkable effect of treating rheumatoid arthritis and is free of toxic and side effects. The methotrexate pharmaceutical composition has the advantages that the methotrexate pharmaceutical composition has an obvious curative effect on treating joint swelling of a patient, especially has an obvious curative effect on improving joint swelling of a patient, can better reduce inflammation indexes ESR and CRP, has more advantages in long-term curative effects on improving joint pressing pain and joint swelling, and can effectively improve the drug effect of methotrexate and reduce toxic / side effects of methotrexate.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

This application discloses a method to solubilize poorly soluble drugs in a liquid crystal vehicle for long-acting injectables. Poorly soluble acidic drugs-hydrophobic basic compounds ion pairs are incorporated into liquid crystal vehicles to solubilize and slowly release the drug after parenteral administration. Ion pairs such as Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine are incorporated into liquid crystal vehicles to solubilize and control release the drugs.

The invention discloses a composition for treating rheumatoid arthritis and application thereof, and belongs to the technical field of medicines. The technical problem to be solved is to provide the composition for treating rheumatoid arthritis, and the composition has a better effect of treating rheumatoid arthritis and is low in cost. The key point of the technical scheme is as follows: the composition for treating rheumatoid arthritis consists of cannabidiol and methotrexate.

This invention relates to the technical field of nanomedicine synthesis and discloses a method for synthesizing nanomedicines for the treatment of rheumatoid arthritis, comprising the following steps: S10: obtaining or preparing high-purity, small-particle-size CaO2 nanoparticles; S20: encapsulating the CaO2 nanoparticles in a ZIF67 system to obtain CaO2@ZIF67; S30: dissolving methotrexate in methanol to obtain an MTX additive solution; dissolving CaO2@ZIF67 in methanol, then adding the MTX additive solution dropwise, and stirring thoroughly; finally, purifying, washing, and drying the obtained product to obtain CaO2@MTX@ZIF67. Targeting the two main pathological features of rheumatoid arthritis, namely inflammation and hypoxic microenvironment, this invention uses ZIF67-loaded calcium peroxide combined with methotrexate to treat the inflammatory sites of rheumatoid arthritis. The constructed product can inhibit the expression of tumor necrosis factor-α / interleukin-6, overcome the hypoxic nature of rheumatoid arthritis, and achieve the technical characteristics of alleviating inflammatory symptoms and altering disease progression, low cost, few side effects, and long-term treatment.

The invention discloses a DNA nanoparticle chip for methotrexate detection and a preparation method and application thereof, and belongs to the technical field of detection.The preparation method comprises the steps that after a silver nanoparticle suspension is centrifuged, a 100 mu M methotrexate aptamer solution with the same volume is added, standing is conducted for 1 h, and the volume is fixed to 80 times of the volume; and dropwise adding 5mu L of the solution to a silicon wafer, and drying at 45 DEG C to form the chip. The detection method comprises the following steps: after serum is subjected to acetonitrile precipitation, dichloromethane extraction, sodium carbonate pH adjustment, centrifugation and solid-phase extraction purification, taking 5 [mu] L, dropwise adding to the chip, drying, carrying out SERS detection, and substituting a signal ratio of 684 cm <-1 > to 1322 cm <-1 > into a standard curve for quantification. The method has stable hotspot construction and molecular capture capabilities, is high in detection sensitivity, only needs 15 minutes in the whole process, and is suitable for rapid monitoring of clinical blood concentration.

The invention discloses a compound for treating osteosarcoma as well as a preparation method and application thereof. The invention belongs to the technical field of biological medicine. The compound is a 13-methyl-palmatine derivative, and has a structure as shown in the following formula. Experiments prove that the compound 13-methyl-palmatine derivative disclosed by the invention can inhibit proliferation, cloning, migration and invasion capabilities of osteosarcoma cells in vitro. An NYG mouse subcutaneous tumor-bearing experiment proves that the traditional Chinese medicine composition can obviously inhibit the growth of osteosarcoma in vivo. Compared with a positive drug (methotrexate intraperitoneal injection), the 13-methyl-palmatine derivative has a more convenient administration mode (intragastric administration), a safer administration dosage and smaller organ and biochemical index damage degree. The invention provides a new technical means for the treatment of osteosarcoma.

Provided herein are compositions comprising disodium levofolinate. Also provided are processes for preparing compositions comprising disodium levofolinate. Also provided are compositions comprising disodium levofolinate prepared by the processes provided herein.Also provided are methods of treating folic acid deficiency in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering 5-fluorouracil and a composition provided herein to the subject. Also provided are methods of reducing the immediate toxic effects of methotrexate overdose in a subject in need thereof, comprisingadministering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering high-dose methotrexate and a composition provided herein to the subject. Also provided are methods of treating megaloblastic anemia in a subject in need thereof, comprising administering a composition provided herein to the subject.

The invention discloses a prescription identification matching method for methotrexate administration, particularly relates to the field of intelligent prescriptions and medical informatics, and is used for solving the problem that in the prior art, a methotrexate administration scheme mainly depends on doctor experience adjustment and is difficult to carry out individualized matching by comprehensively utilizing historical case data. A disease activity manifold trajectory is constructed by extracting historical clinical records in electronic medical records of a target patient, a delay accumulation rule of disease state change after administration is analyzed in combination with prescription records to obtain drug effect attenuation state parameters, patient attenuation subtypes are identified on the basis, and causal relationship analysis is performed to obtain a causal contribution weight vector; and searching similar patient groups from a historical case library, generating a candidate intervention track set containing success probability distribution, and finally generating a methotrexate administration scheme recommendation list according to success probability sorting, thereby providing a more reasonable methotrexate administration scheme with reference value for a target patient.

A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

The invention belongs to the technical field of biological medicines, and particularly relates to application of Venetoclax in preparation of an anti-inflammatory drug, in particular to a drug for treating rheumatoid arthritis (RA) with insufficient (MTX-IR) by using methotrexate. It is found for the first time that Venetoclax can induce apoptosis of inflammatory T cells of peripheral blood or synovial fluid of rheumatoid arthritis patients with insufficient curative effect on methotrexate, and occurrence and development of inflammation are inhibited by reducing the number of the inflammatory T cells, so that Venetoclax has the prospect of being developed into drugs for treating rheumatoid arthritis and anti-inflammatory and immunomodulatory drugs.

This disclosure provides double-stranded nucleic acid compositions incorporating uracil, gemcitabine, and methotrexate (MTX). More specifically, this disclosure reveals that modification of double-stranded microRNA nucleotide sequences with 5-fluorouracil, gemcitabine, and methotrexate (MTX) enhances the therapeutic efficacy and tumor specificity of tumor suppression. Accordingly, this disclosure provides various nucleic acid (e.g., microRNA) compositions incorporating 5-fluorouracil, gemcitabine, and methotrexate (MTX) into their nucleic acid sequences, as well as methods for using them. This disclosure further provides pharmaceutical compositions (e.g., formulations) containing the modified nucleic acid compositions, and methods for treating cancers such as pancreatic cancer. This is a platform technology that can be applied to other tumor suppressor miRNAs and siRNAs.

The present invention relates to a method of treating a patient with moderate to severe active rheumatoid arthritis and inadequate response to Methotrexate by administering to the patient a therapeutically effective amount of compound of Formula 001: or a stereoisomer, racemate, tautomer, isotopologue, prodrug, or pharmaceutically acceptable salt thereof.

Methotrexate-containing polymersomes and methods for treating ectopic pregnancy or for treating gestational choriocarcinoma using the methotrexate-containing polymersomes.

The present invention discloses a cell membrane nanoparticle and its preparation method and use. + T cells, cell membrane nanoparticles TaCD4M1-NP with ROS response. This nanoparticle can carry CD4 + T cells infiltrate the inflammatory site and rely on the membrane proteins of the cell membrane to achieve enrichment and retention in the inflammatory site, increase the drug concentration in the target site, and reduce toxic and side effects. By selecting a combination of anti-inflammatory drugs, methotrexate and dasatinib were selected for combined administration. The results showed that the combination had synergistic efficacy in various inflammatory models. Cell membrane nanoparticles loaded with MTX and DAS can effectively carry CD4 + T cells, which infiltrate inflammatory sites such as the colon in ulcerative colitis (UC) and the joints in rheumatoid arthritis (RA), significantly enhance the efficacy of drugs against UC and RA, providing a new approach for the treatment of inflammatory diseases.

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.

This invention discloses a halogen-free organic solderable protective agent and its preparation method, comprising the following components at the following mass concentrations: 2-phenylimidazolium 2.5-5 g / L, 2-benzylbenzimidazole 0.5-1.0 g / L, pyromellitic anhydride 30-60 mg / L, diethylene glycol 1-2 ml / L, ethanol 5-10 ml / L, p-nitrobenzoic acid 10-30 mg / L, and methotrexate 10-30 mg / L; the temperature is 35-45℃; the pH is controlled within the range of 3.8-4.2; and the balance is deionized water. This invention can be widely applied to the surface treatment process of electronic products, achieving a thickness rate of over 0.35 μm in 1 minute. The resulting film is uniform, transparent, and glossy, with strong solderability. It exhibits good resistance to sulfuric acid concentrations below 0.1 mol / L and readily dissociates in 5% hydrochloric acid and 5 ml / L acetone solutions, simplifying rework.

Disclosed are a pharmaceutical combination of pimozide and methotrexate and use thereof. The pharmaceutical combination comprises methotrexate, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of pharmaceutically acceptable salt thereof, and pimozide, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of pharmaceutically acceptable salt thereof. The pharmaceutical combination can be used for the treatment of rheumatoid arthritis.

A method for treating moderate to severe active rheumatoid arthritis in a patient, which method comprises administering, to the patient, a therapeutically effective amount of a compound as shown in 001, a stereoisomer, racemate, tautomer, isotopic marker, prodrug thereof or a pharmaceutically acceptable salt thereof; and the patient responds poorly to methotrexate. The compound as shown in formula 001 has the below structure.